Pipeline / Targeted Indication / Pulmonary Hypertension (PH) WHO Group 3

INCREASE - Phase III clinical trial with Tyvaso® (treprostinil) for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Phase III clinical trial with Tyvaso® (treprostinil) for the treatment of pulmonary hypertension due to chronic obstructive pulmonary disease (PH-COPD).